Asher Biotherapeutics, Inc. aims to get around the problem of pleiotropy – engagement of a target across a variety of cells in the body, causing unintended side effects – by developing cell-targeted immunotherapies that engage two targets on the same immune cell. The company said on 1 September that it closed a $108m series B venture capital round to advance AB248, an interleukin-2 (IL-2) mutein targeting CD8-positive T-cells, into the clinic and to progress additional programs.
South San Francisco-based Asher Bio has an initial focus on cancer with plans to also develop cell-, or cis-targeted, immunotherapies for autoimmune and infectious diseases
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?